APA (7th ed.) Citation

Nesterova, E. S., Klitochenko, T. Y., Glonina, N. N., Fadeeva, N. V., Sannikova, T. A., Lyalina, I. S., . . . Poddubnaya, I. V. (2021). Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: Empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy. IP Habib O.N.

Chicago Style (17th ed.) Citation

Nesterova, Ekaterina S., et al. Interim Results of a Multicenter Retrospective-prospective Observational Post-marketing Study of Extimia® BIOCAD (INN: Empegfilgrastim) to Evaluate Safety and Efficacy in Patients with Lymphoproliferative Diseases Receiving Cytotoxic Therapy. IP Habib O.N, 2021.

MLA (8th ed.) Citation

Nesterova, Ekaterina S., et al. Interim Results of a Multicenter Retrospective-prospective Observational Post-marketing Study of Extimia® BIOCAD (INN: Empegfilgrastim) to Evaluate Safety and Efficacy in Patients with Lymphoproliferative Diseases Receiving Cytotoxic Therapy. IP Habib O.N, 2021.